DraftCapital BluecrossPolicy MP 2.372

Occipital Nerve Stimulation

This policy governs coverage and medical necessity determinations for occipital nerve stimulation for headaches (including migraine, cluster, hemicrania continua) for Capital Blue Cross products and affected programs.

Policy Summary

PayerCapital Bluecross

PolicyOccipital Nerve Stimulation

Policy CodePolicy MP 2.372

Change TypeAnnual effective-date publication

Effective Date1/1/2025

Next Review Date

Key ActionVerify member benefit plan and preauthorization requirements with Capital Blue Cross before providing services.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

investigationalcoverage stance

5sham-controlled RCTs

no device clearedFDA status

1/1/2025effective date

MP 2.372policy id

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

General coverage stance

Covered when ALL of the following are met

Policy stance: Occipital nerve stimulation is considered investigational for all indications due to insufficient evidence of net health benefit.

See summary of evidence: mixed findings from randomized controlled trials (including 5 sham-controlled RCTs), pooled analyses with mixed results, reduction in days with prolonged moderate-to-severe headache but no consistent response-rate benefit, and substantial minor and serious adverse events.

Not covered — investigational

Occipital nerve stimulation coverage stance from policy history

Investigational statement: Occipital nerve stimulation is considered investigational for all indications.

From policy history entry documenting the policy creation and subsequent consensus reviews with no change to the policy statement.

FDA/regulatory status: The U.S. Food and Drug Administration has not cleared or approved any occipital nerve stimulation device for the treatment of headache. Existing device approvals are for other indications (for example, certain implantable pulse generators have FDA approval for chronic pain or spinal cord stimulation), and use for headache would be off‑label.

Policy history documents the investigational designation: Occipital nerve stimulation is considered investigational for all indications. The policy entry shows the investigational stance established at policy creation and confirmed through subsequent consensus reviews (no change to the policy statement).

Coverage statement and rationale: Occipital nerve stimulation is considered investigational and therefore not medically necessary for all indications because available evidence is insufficient to demonstrate a net health benefit for headache treatment. No device has FDA clearance or approval specifically for headache, and clinical trial data (including randomized trials and systematic reviews) do not provide conclusive evidence of consistent benefit to outweigh harms.

Occipital nerve stimulation is considered investigational for all indications.

Provider Actions / Prior Authorization

Prior Authorization

Plan-based authorization

Authorization and benefit determinations depend on the member's specific health benefit plan. Verify coverage, benefit limits, exclusions, and whether preauthorization is required with the member's plan prior to providing services.

Preauthorization requirement varies by plan — contact Capital Blue Cross or consult the member's benefit documents to confirm.
Presence of this medical policy does not guarantee coverage; the member's health benefit plan language governs.

Prior Authorization

Preauthorization requirement depends on member's plan

Providers must verify whether prior authorization is required for occipital nerve stimulation for each member. Do not assume coverage based on this policy; obtain benefit verification and any required authorizations before scheduling procedures.

Contact Capital Blue Cross Provider Services or Member Services for plan-specific prior authorization requirements.
Confirm benefit limits, exclusions, and any step-therapy or trial-of-therapy prerequisites in the member's plan.

Documentation Required

Prior medical management expected

Prior medical management is generally expected before device-based interventions for headache disorders. Ensure conservative therapies have been tried and documented per the member's plan requirements.

Document trials of preventive medications (e.g., amitriptyline, propranolol, topiramate) and appropriate behavioral therapies (e.g., biofeedback, relaxation training).
If the plan requires step therapy or documentation of treatment failure, include records showing inadequate response to or intolerance of prior therapies.

Note

Benefit verification required

Consult the member's health benefit plan for coverage, exclusions, limits, and preauthorization requirements. If plan details are unclear, contact Capital Blue Cross for benefit information and provider contact details.

Benefit verification is required for all members — the policy alone does not determine coverage.
For questions about application of this policy to a specific member, contact Capital Blue Cross Provider Services or Member Services.

Denial Risk

Investigational designation and benefit variation

Investigational designation may affect coverage depending on the member's plan. This procedure is considered investigational for all indications per the medical policy; benefit determinations and coverage decisions are plan-specific.

Occipital nerve stimulation is designated investigational — many plans may not cover investigational services.
Even if a policy exists, the member's plan language controls coverage; verify benefits before proceeding.

Background

Background: Occipital nerve stimulation (ONS) is an implanted neuromodulation system that delivers electrical stimulation to the occipital nerves using subcutaneous leads connected to an implantable pulse generator. Implantation typically involves placement of electrodes over one or both occipital nerves with a tunneled extension to a subcutaneous pulse generator, providing continuous or intermittent stimulation intended to reduce frequency or severity of refractory headaches such as migraine, cluster headache, or hemicrania continua. The evidence base includes randomized controlled trials and observational series but is insufficient to support routine clinical use.

Definitions

Chronic headache / primary chronic headache definition

DefinitionPrimary chronic headache: headache occurring more than 15 days per month for at least 3 consecutive months.

Related types discussedIncludes vascular-type headaches such as migraine, hemicrania continua, and cluster headache.

Clinical impactEstimated 45 million Americans experience chronic headaches; about half have severe or disabling symptoms.

Occipital nerve stimulation (ONS) definition — implanted system components

System componentsSubcutaneously implanted pulse generator (placed in chest wall or abdomen).

ConnectionExtension leads tunneled from the pulse generator to electrodes placed over one or both occipital nerves at the base of the skull.

Stimulation modeProvides continuous or intermittent electrical stimulation to the occipital nerves.

Intended useIntended to prevent migraines and other headaches in patients refractory to medication.

NIA (definition entry)

TermNIA

Definition available in sourceNo definition text provided in the source document for this term.

Location in policyListed in Definitions section (V. DEFINITIONS) without accompanying explanatory text.

L8681	stated in document as Procedure Codes L8681
61886	stated in document as Procedure Codes 61886
L8682	stated in document as Procedure Codes L8682
64568	stated in document as Procedure Codes 64568
L8683	stated in document as Procedure Codes L8683
64569	stated in document as Procedure Codes 64569
L8684	stated in document as Procedure Codes L8684
64999	stated in document as Procedure Codes 64999
L8685	stated in document as Procedure Codes L8685
L8686	stated in document as Procedure Codes L8686

OpenPayer

Occipital Nerve Stimulation

Coverage Criteria

Coding and Billing

Provider Actions / Prior Authorization

Background

Definitions